Anacor Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ANACOR PHARMS INC
ANACOR PHARMS INC has two approved drugs.
There are four US patents protecting ANACOR PHARMS INC drugs.
Summary for Anacor Pharms Inc
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Anacor Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,168,614*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 9,682,092*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,501,712*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,039,451*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ANACOR PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 5% | ➤ Subscribe | 2018-07-09 |
International Patents for Anacor Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20150113219 | ⤷ Start Trial |
| South Korea | 20140082842 | ⤷ Start Trial |
| Cyprus | 1121899 | ⤷ Start Trial |
| Cyprus | 1120695 | ⤷ Start Trial |
| South Africa | 201506944 | ⤷ Start Trial |
| South Korea | 101819869 | ⤷ Start Trial |
| Denmark | 2987796 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Anacor Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2343304 | 20C1024 | France | ⤷ Start Trial | PRODUCT NAME: CRISABOROLE, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | 757 | Finland | ⤷ Start Trial | |
| 2343304 | 132020000000082 | Italy | ⤷ Start Trial | PRODUCT NAME: CRISABOROLO, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE(STAQUIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1421, 20200401 |
| 2343304 | 2020/024 | Ireland | ⤷ Start Trial | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/19/1421/001 EU/1/19/1421/004 20200327 |
| 2343304 | 301049 | Netherlands | ⤷ Start Trial | PRODUCT NAME: CRISABOROLE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | SPC/GB20/025 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/19/1421 20200401; UK PLGB 00057-1691 20200401 |
| 2343304 | C20200027 00352 | Estonia | ⤷ Start Trial | PRODUCT NAME: KRISABOROOL;REG NO/DATE: EU/1/19/1421 01.04.2020 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
